NCT05528588CompletedPhase 2
Furoscix in Heart Failure Patients With Diuretic Resistance
Efficacy of Furoscix in Heart Failure Patients With Diuretic Resistance
Source: ClinicalTrials.gov · Last updated 16 Jul 2025
Brief summary (registry, in English)
This will be a randomized, open-label pilot study of 70 patients with and without diuretic resistance who were recently admitted and discharged for acute decompensated heart failure with and oral diuretic regimen testing whether Furoscix is more effective at achieving post-discharge outpatient diuresis than standard of care. Diuretic resistance will be identified using the BAN-ADHF (BUN, creAtinine, NP-levels, Age, Diabetes and DBP, HF hospitalization, and atrial Fibrillation) score which has been integrated into the electronic health record. The score is integer-based with a score of ≥ 12 indicating diuretic resistance with high likelihood of poor outcomes. The primary outcome is diuretic efficacy as measured by volume of urine produced 8 hours after treatment and urine sodium levels (assessed hourly or per urination episode within 8 hours of treatment).
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (actual)
- First submitted
- 31 Aug 2022
- Start date
- 2 Jun 2023
- Primary completion date
- 22 Apr 2024
- Lead sponsor
- University of Texas Southwestern Medical Center
- Diseases
- Heart failure
- NCT number
- NCT05528588
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 70
- From 2 Jun 2023 to the primary completion date, 22 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior heart transplantation or left ventricular assist device
- Concurrent use of non-loop diuretic
Other illness
- Low-output heart failure
- Advanced liver disease
- Skin/Soft tissue condition precluding Furoscix
Lab values
- Chronic kidney disease stage 5 (eGFR\<20) or End Stage Kidney Disease
Other
- Systolic blood pressure \<100
- ICU hospitalization within 3 months
- Inotrope use within last 3 months
- Home inotropes
- Electrolyte abnormalities on discharge
- Inadequate data for BAN-ADHF score
- Pregnant
- Severe malnutrition
- Inability to collect urine
Who the study is looking for
- English-speaking patients discharged after ward hospitalization for acute decompensated heart failure
- Able to be screened and enrolled within 14 days of hospitalization
- Recent echocardiogram (6 months or less)
- Discharged with home diuretic regimen
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UT Southwestern Medical Center Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.